• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

作者信息

Bryce Alan H, Borad Mitesh J, Egan Jan B, Condjella Rachel M, Liang Winnie S, Fonseca Rafael, McCullough Ann E, Hunt Katherine S, Ritacca Nicole R, Barrett Michael T, Patel Maitray D, Young Scott W, Silva Alvin C, Ho Thai H, Halfdanarson Thorvardur R, Stanton Melissa L, Cheville John, Swanson Scott, Schneider Daniel E, McWilliams Robert R, Baker Angela, Aldrich Jessica, Kurdoglu Ahmet, Izatt Tyler, Christoforides Alexis, Cherni Irene, Nasser Sara, Reiman Rebecca, Cuyugan Lori, McDonald Jacquelyn, Adkins Jonathan, Mastrian Stephen D, Von Hoff Daniel D, Craig David W, Stewart A Keith, Carpten John D

机构信息

Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN.

Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN.

出版信息

Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1.

DOI:10.1016/j.clgc.2016.11.001
PMID:28057415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7513310/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20af/7513310/55dc5d19ce0e/nihms-1622510-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20af/7513310/77ceb2838296/nihms-1622510-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20af/7513310/55dc5d19ce0e/nihms-1622510-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20af/7513310/77ceb2838296/nihms-1622510-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20af/7513310/55dc5d19ce0e/nihms-1622510-f0002.jpg

相似文献

1
Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.转移性黏液性尿道腺癌的综合基因组分析指导精准肿瘤治疗：可靶向的表皮生长因子受体（EGFR）扩增导致厄洛替尼治疗成功
Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1.
2
EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.表皮生长因子受体（EGFR）和 HER3 信号通路阻断治疗携带 NRG1 融合的浸润性黏液性腺癌。
Lung Cancer. 2018 Oct;124:71-75. doi: 10.1016/j.lungcan.2018.07.026. Epub 2018 Jul 20.
3
Genome-wide DNA Methylation Analysis Reveals as a Novel Epigenetic Target for 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment.全基因组 DNA 甲基化分析显示 是 19 号缺失肺腺癌诱导厄洛替尼治疗的新型表观遗传靶标。
Clin Cancer Res. 2017 Sep 1;23(17):5003-5014. doi: 10.1158/1078-0432.CCR-16-2688. Epub 2017 May 10.
4
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.在未经TKI治疗的EGFR-L858R突变肺腺癌中，新发ERBB2扩增导致对厄洛替尼产生内在抗性。
Lung Cancer. 2017 Dec;114:108-110. doi: 10.1016/j.lungcan.2017.08.018. Epub 2017 Aug 24.
5
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.在德国晚期肺腺癌患者中基于表皮生长因子受体（EGFR）突变检测提供厄洛替尼的个体化一线治疗策略的成本效益
Pharmacoeconomics. 2015 Nov;33(11):1215-28. doi: 10.1007/s40273-015-0305-8.
6
Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.在厄洛替尼耐药的肺腺癌中，MET基因拷贝数的异质性和表皮生长因子受体（EGFR）突变导致原发灶和转移灶对克唑替尼产生不一致的反应。
Lung Cancer. 2018 Oct;124:317-319. doi: 10.1016/j.lungcan.2018.03.016. Epub 2018 Mar 17.
7
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.厄洛替尼/克唑替尼联合治疗一名原发性EGFR突变加继发性MET扩增且获得新型克唑替尼耐药突变MET G1108C的肺腺癌患者。
Ann Oncol. 2017 Oct 1;28(10):2622-2624. doi: 10.1093/annonc/mdx324.
8
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).表皮生长因子受体扩增和敏感突变与厄洛替尼（MutP-CLICaP）治疗肺腺癌患者的生存相关。
Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x.
9
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).西班牙裔人群中表皮生长因子受体突变阳性肺腺癌患者对厄洛替尼获得性耐药（CLICaP）
Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.
10
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.胰岛素样生长因子-1 受体抑制克服黏液性肺腺癌对吉非替尼的耐药性。
J Pathol. 2011 Sep;225(1):83-95. doi: 10.1002/path.2897. Epub 2011 May 19.

引用本文的文献

1
Editorial Comment to Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma.关于黏液性尿道腺癌和前列腺腺癌并存的系统治疗的编辑评论
IJU Case Rep. 2020 Sep 4;3(6):264-265. doi: 10.1002/iju5.12218. eCollection 2020 Nov.
2
Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma.黏液性尿道腺癌和前列腺腺癌并存的全身治疗。
IJU Case Rep. 2020 Aug 2;3(6):261-264. doi: 10.1002/iju5.12210. eCollection 2020 Nov.

本文引用的文献

1
Mucinous Adenocarcinoma of the Male Urethra: A Report of Two Cases.男性尿道黏液腺癌：两例报告
Anal Quant Cytopathol Histpathol. 2015 Aug;37(4):267-72.
2
Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma.原发性尿道癌的预后因素及结局：原发性尿道癌国际协作研究结果
World J Urol. 2016 Jan;34(1):97-103. doi: 10.1007/s00345-015-1583-7. Epub 2015 May 17.
3
Primary enteric-type mucinous adenocarcinoma of the urethra in a patient with ulcerative colitis.
一名溃疡性结肠炎患者发生的尿道原发性肠型黏液腺癌。
Int Surg. 2014 Sep-Oct;99(5):669-72. doi: 10.9738/INTSURG-D-13-00073.1.
4
Primary mucin-producing urothelial-type adenocarcinoma of the prostatic urethra diagnosed on TURP: a case report and review of literature.经 TURP 诊断的前列腺尿道原发性黏液产生型尿路上皮型腺癌：病例报告及文献复习。
BMC Urol. 2014 May 22;14:39. doi: 10.1186/1471-2490-14-39.
5
Prognostic factors in male urethral cancer.男性尿道癌的预后因素。
Cancer. 2011 Jun 1;117(11):2426-34. doi: 10.1002/cncr.25787. Epub 2010 Dec 14.
6
Mucin-producing tumors and tumor-like lesions involving the prostate: a comprehensive review.分泌黏液的前列腺肿瘤和肿瘤样病变：全面综述。
Adv Anat Pathol. 2012 Nov;19(6):374-87. doi: 10.1097/PAP.0b013e318271a361.
7
Incidence and survival of rare urogenital cancers in Europe.欧洲罕见泌尿生殖系统癌症的发病率和生存率。
Eur J Cancer. 2012 Mar;48(4):456-64. doi: 10.1016/j.ejca.2011.10.031. Epub 2011 Nov 24.
8
Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.原发性前列腺黏液分泌性尿路上皮型腺癌：15例报告
Am J Surg Pathol. 2007 Sep;31(9):1323-9. doi: 10.1097/PAS.0b013e31802ff7c4.
9
Incidence of primary urethral carcinoma in the United States.美国原发性尿道癌的发病率。
Urology. 2006 Dec;68(6):1164-8. doi: 10.1016/j.urology.2006.08.1057. Epub 2006 Dec 4.
10
Mucinous adenocarcinoma of posterior urethra. Report of a case.后尿道黏液腺癌。病例报告。
Pathol Res Pract. 2005;201(2):137-40. doi: 10.1016/j.prp.2004.12.002.